Why the study?
Pregnancy management and risk stratification in women with CHD are challenging due to physiological haemodynamic changes, requiring comparison of existing cardiovascular risk scores.
Which pregnancy cardiovascular risk score best predicts maternal complications in pregnant women with congenital heart disease?
Which pregnancy cardiovascular risk score best predicts maternal complications in pregnant women with congenital heart disease?
The modified WHO classification is the most accurate among existing risk scores for predicting cardiovascular complications in pregnant women with congenital heart disease.
Answers are grounded in this paper and cite their sources.
May support modified WHO for risk stratification in pregnant CHD patients; leaves open need for prospective validation before wider adoption.
BACKGROUND: Management of pregnancy and risk stratification in women with congenital heart diseases (CHD) are challenging, especially due to physiological haemodynamic modifications that inevitably occur during pregnancy. AIMS: To compare the accuracy of the existing pregnancy cardiovascular risk scores in prediction of maternal complications during pregnancy in CHD patients. METHOD AND RESULTS: From 2007 to 2018, all pregnant women with a CHD who delivered birth after 20 weeks of gestation were identified. The discriminating power and the accuracy of the five existing pregnancy cardiovascular risk scores [CARPREG, CARPREG II, HARRIS, ZAHARA risk scores, and modified WHO (mWHO)] were evaluated.Out of 104 pregnancies in 65 CHD patients, 29% experienced cardiovascular complications during pregnancy or post-partum. For the five scores, the observed rate of cardiovascular events was higher than the expected risk. The values of area under the ROC curve were 0.75 (0.62-0.88) for mWHO, 0.65 (0.53-0.77) for CARPREG II, 0.60 (0.40-0.80) for HARRIS, 0.59 (0.47-0.72) for ZAHARA, and 0.58 (0.43-0.73) for CARPREG. CONCLUSION: The modified WHO classification appeared to better predict cardiovascular outcome in pregnant women with CHD than the four other existing risk scores.Clinical Trial Registration: Clinicaltrials.gov: NCT04221048.
No takes yet. Share an insight, caveat, or question.
Bredy et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: